Loading...
•
Jun 30, 2021
Guardant Health Q2 2021 Earnings Report
Reported revenue of $92.1 million, driven by a 52% year-over-year growth in clinical volume.
Key Takeaways
Guardant Health reported a revenue of $92.1 million for the second quarter of 2021, a 39% increase compared to the same period in 2020. The company saw growth in clinical and biopharmaceutical tests, and expanded its product portfolio.
Revenue of $92.1 million for the second quarter of 2021, an increase of 39% over the corresponding period of 2020
Reported 20,830 tests to clinical customers and 3,653 tests to biopharmaceutical customers in the second quarter of 2021, representing an increase of 52% and 30%, respectively, over the second quarter of 2020
Enrolled 10,000th patient in ECLIPSE trial and plans to launch a blood-based screening LDT in the first half of 2022
Expanded Guardant360 portfolio with launch of TissueNext™ and Response™ tests
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Due to continued uncertainty around the global COVID pandemic, Guardant Health is maintaining its previous 2021 revenue guidance. The Company continues to expect full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020. Clinical volumes for 2021 are expected to be greater than 90,000 tests, growing at least 42% over 2020.